Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters

Table 3 Linear regression models to predict DAS28 and HAQ score at the fifth year of follow-up

Variables^a	DAS28 at the fifth year^b	HAQ at the fifth year^c
Male sex	0.64, (0.005 to 1.28), 0.05
Baseline DAS28	0.24, (0.09 to 0.38), 0.002
Months of persistence duration during the first 4 years	−0.28, (−0.045 to −0.011), 0.002	−0.12, (−0.019 to −0.005), 0.001
Age		0.10, (0.004 to 0.016), 0.001

DAS28 Disease Activity Score in 28 joints, HAQ Health Assessment Questionnaire
^aData are presented as β coefficients (95 % confidence interval), p value
^b R ² = 0.338
^c R ² = 0.281

ISSN: 1478-6362